There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Bevacizumab was approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. There are also biosimilars of bevacizumab available, such as bevacizumab-awwb, bevacizumab-maly, and bevacizumab-adcd.
Interestingly, researchers have identified higher VEGF expression in patients with COVID-19, which may contribute to lung pathologies including acute respiratory syndrome (ARDS) and acute lung injury (ALI). As such, bevacizumab is being investigated for the treatment of lung complications associated with severe cases of COVID-19.
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer; and recurrent glioblastoma.
Interestingly, bevacizumab is currently under investigation for the treatment of COVID-19 complications including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Yonsei University Hospital, Seoul, Korea, Republic of
Asan Medical Center, Seoul, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
The University of British Columbia, Vancouver, British Columbia, Canada
The University of Alberta and Capital Health, Edmonton, Alberta, Canada
Dr. Stanley G. Shortt, Victoria, British Columbia, Canada
Pfizer Investigational Site, Madrid, Spain
Masoud Soheilian, Tehran, Iran, Islamic Republic of
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of
Indiana University Cancer Center, Indianapolis, Indiana, United States
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
Community Regional Cancer Center, Indianapolis, Indiana, United States
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.